{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-026913","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2023-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.087953+00:00","generated_at":"2026-06-14T05:15:42.629514+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Candel Therapeutics (CADL) appoints Nicoletta Loggia, PhD, RPh to board effective June 7, 2023","bullets":["Board size increased from 9 to 10; Dr. Loggia appointed as Class III director with term expiring at 2024 annual meeting.","She receives option for 28,480 shares vesting over 3 years plus standard non-employee director cash compensation.","Dr. Loggia is CTO at Orchard Therapeutics, formerly Global Head of Cell & Gene Therapies at Novartis, with 20+ years experience.","Appointment adds manufacturing expertise as company approaches phase 3 pivotal readout in localized prostate cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-026913","json":"https://secwatch.observer/filing/0000950170-23-026913.json","markdown":"https://secwatch.observer/filing/0000950170-23-026913.md","text":"https://secwatch.observer/filing/0000950170-23-026913.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023026913/0000950170-23-026913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023026913/cadl-20230605.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T05:15:42.629514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3431a1345e","claim":"Nicoletta Loggia was appointed as Class III Director at Candel Therapeutics, Inc..","evidence_excerpt":"unanimously appointed Nicoletta Loggia, Ph.D., R.Ph., to fill the newly created vacancy on the Board, effective June 7, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023026913/0000950170-23-026913-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}